Subsequently, a prospective study, the CREDENCE trial, enrolled patients with type 2 diabetes and albuminuria (albumin/creatinine ration 300–5000 mg/g) and chronic kidney disease (glomerular filtration rate: GFR of 30–90 mL/min/1.73 m2) that were randomized to the SGLT2 inhibitor canagliflozin at a dose of 100 mg daily or placebo. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.